Chloroquine can treat COVID-19 at early stage – NAFDAC DG

The Director-General of the National Agency for Food and Drug Administration and Control (NAFDAC) Prof Mojisola Adeyeye,  has said that chloroquine is effective in the treatment of COVID-19 at the early stage of infection, going by research findings.

Adeyeye, who spoke on Tuesday during a virtual news conference in Abuja, however  said  that chloroquine could only  be used as prophylactics, adding that countries like Ghana and Senegal have also embraced the clinical use of chloroquine for treatment.

- Advertisement -

She said, “On March 20, this year, I had a press briefing. At that time, people did not understand the meaning of clinical trial treatment. Once they hear treatment, they think you can use it anyhow. But clinical trial treatment is a research study to see whether the drug will work or not.

“At the press briefing, I said I was going through literature to see what others have done and I saw in a particular literature, a reliable publication of an article, about chloroquine and remdesivir.

- Advertisement -

“They said in the cell culture, remdesivir and chloroquine killed COVID-19 viruses, that is, invitro – in the laboratory. But you cannot translate that to humans unless a clinical trial is done.

READ ALSO: LASG seals RCCG, eatery, others over environmental offence

“I kept looking. About two weeks or so later in early March; there was a publication where 100 patients were treated with chloroquine across ten hospitals in six cities, including Wuhan. It said that all of them recovered from the symptoms. They called it that time pneumonia symptom.

“In the cells; in the lab, remdesivir and chloroquine killed COVID-19. We did not know that the disease has four stages that include pre-exposure, early-stage, severe stage and post-infection.

“At what stage would they be more effective? We didn’t know at that point. Now, we are realising that chloroquine is effective at the early stage.”

The Director-General added, “Now we are talking of remdesivir. We met with Gilead – the maker of remdesivir about two months ago and they came. They said they have licensed their drug to five Indian companies and one Pakistani company.  To treat an average patient will cost about $10 with chloroquine and cost about $2,500 with remdesivir.

“When we now got the profile of remdesivir, what was recorded in literature and from the manufacturer was that remdesivir doesn’t work at the early stage. It works at the late stage. But when viruses are in the tube in the laboratory, you won’t know which is late or which is early. Both killed them. We now understand that it is not only one drug that can be effective for COVID-19, but it depends on the stage and the phases of the disease.”